Advertisement

Topics

Novel integrin peptide therapy yields visual acuity gains on par with Avastin for DME

08:32 EDT 24 Aug 2017 | Healio

BOSTON — Sequential therapy with 1 mg ALG-1001 yielded equivalent visual acuity gains as treatment with bevacizumab monotherapy in patients with diabetic macular edema, according to a study presented here.“The safety profile was excellent. There was very little in the way of [serious adverse events] at all,” David Boyer, MD, said at the American Society of Retina Specialists meeting, where he delivered topline results for the phase 2 stage 2 DEL MAR study.

Original Article: Novel integrin peptide therapy yields visual acuity gains on par with Avastin for DME

NEXT ARTICLE

More From BioPortfolio on "Novel integrin peptide therapy yields visual acuity gains on par with Avastin for DME"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...